Transforming the Blood Collection Tube market

Serum is the gold standard for biochemical analysis. Serum is produced when a blood sample clots and the clotted cells are removed by centrifugation. Preparation of high quality Pre-analytical samples is important to ensure accurate analytical results and patient outcomes. Current tubes use an inefficient clot activator and are unable to clot the blood of some patients – such as anticoagulated cardiac patients or those taking common medicines such as warfarin or other oral anticoagulants. The rapid production of high quality serum is important to improve laboratory efficiency and is vital to optimize patient outcomes.

For many years, the industry has recognized the need for a tube that rapidly produced high quality serum from the majority of blood samples. Q-Sera’s technology has been developed to create a new standard biochemistry tube to meet these needs and uses pro-coagulant proteins called prothrombin activators, the use of which is covered by global patent protection. These proteins are found in the venom of some snakes (including the Australian Taipan) that have a potent ability to coagulate the blood and are now manufactured ‘recombinantly’ using industry standard protein production technologies.

RAPClot® Rapid serum tubes contain RAPClot®, recombinant ecarin and a patented protective formulation.

Recent achievements:

  • Exclusive agreement with Terumo Corporation to commercialise RAPClot Rapid serum tubes in Japan
  • Q-Sera and Bora Biologics Co., Ltd working on recombinant ecarin


RAPClot® (recombinant ecarin)

High purity RAPClot® is recombinantly manufactured using standard biopharmaceutical manufacturing and purification processes. The process is high yielding, low cost and highly scalable with a master cell bank ready for use.

As a recombinantly manufactured protein, supply of RAPClot® is unlimited. In line with standard practice, RAPClot® can be manufactured at any required Quality level.